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I read with great interest the paper by Amin et al., titled "There Is No Advantage to Transpapillary Pancreatic Duct Stenting for the Transmural Endoscopic Drainage of Pancreatic Fluid Collections: A Meta-Analysis" published in the July 2017 issue of *Clinical Endoscopy* \[[@b1-ce-2017-101]\]. The authors concluded that transpapillary pancreatic duct (PD) drainage provides no additional clinical benefit for transmural (TM) peripancreatic fluid collections (PFC) and, therefore, patients with TM drainage may not require PD intervention.

However, I have a concern about the authors' conclusion, because the statistical significance was not identified in their meta-analyses between TM and CD. To interpret the results correctly, they had to say that "the clinical benefit of transpapillary pancreatic duct dranage in addition to the transmural dranage was not identified in our meta-analyses." In addition, confidence intervals were too wide in the meta-analyses. The 95% confidence interval for technical success, for example, was 0.367-3.365. Although the odds ratio was close to 1, it was difficult to be sure that TM was equivalent to CD because of the wide confidence interval. More studies in this issue may change the conclusion.

Recently, endoscopic ultrasound (EUS)-guided drainage of the PFC has been widely accepted as a safe and effective standard technique compared with surgical approaches. Especially, EUS-guided drainage with a fully covered metal stent is associated with higher technical and functional success, shorter procedural time, and fewer short- and long-term adverse events \[[@b2-ce-2017-101]\]. Among the several long-term adverse events, the major concern with this procedure is regarding the recurrence after the removal of TM stent. In one study reporting medium-term assessment of EUS-guided drainage of the PFC \[[@b3-ce-2017-101]\], the authors demonstrated that there were 6 (10%) cases of symptomatic recurrence of PFC. In general, persistent or recurrent PFC might be attributed to PD injury or leakage \[[@b4-ce-2017-101]\]. Therefore, any leakage observed during imaging before or after metal stent placement would require an additional procedure, such as PD stenting. According to some expert opinions \[[@b2-ce-2017-101]\], this strategy probably prevented further recurrence because the leakage healed by the time of follow-up, and the PD stent could be removed. This finding is similar to that of two recent studies \[[@b5-ce-2017-101],[@b6-ce-2017-101]\] in which an additional PD stent in patients with partial disruptions, but not in those with total disruptions, was found to improve the clinical outcomes compared with TM alone in patients with PFC. Furthermore, Trevino et al. reported that PD stenting might be one of the significant factors affecting the treatment success based on multi-variable analysis \[[@b5-ce-2017-101]\].

From the opposite perspective, the technical difficulty of PD stenting in patients who underwent CD was theoretically higher compared to TM alone. Generally, the technical suc- cess rate of PD stenting varied from 17.5% to 40.2% \[[@b5-ce-2017-101],[@b7-ce-2017-101]\], because PD cannulation may be more difficult than biliary cannulation in some cases. Common causes of PD stenting failure include complete PD disruption, significant PD stricture or obstruction, inability to selectively perform deep PD cannulation, surgically altered anatomy, or luminal stricture that precludes the passage of the endoscope \[[@b6-ce-2017-101],[@b8-ce-2017-101]\]. Furthermore, difficult PD cannulation necessarily results in prolonged and frequent papillary manipulation, and repeated attempts at cannulation, regardless of the injection of contrast into the PD, are known to increase the risk of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP), especially in high-risk patients with one or more patient-related risk factors for PEP (such as younger age or female sex) \[[@b9-ce-2017-101]\].

In summary, there has been, to date, no evidence indicating which intervention is better regarding the efficacy and safety of PFC treatment through direct comparisons between TM alone and CD. Thus, the choice of appropriate intervention for complete resolution and prevention of the recurrence of PFC should be made according to the status of PD disruption/leakage (partial or complete), technical difficulty of PD cannulation and stenting, characteristics and location of the PFC, and the possibility of recurrence. Additionally, further studies are needed to compare the efficacy and safety between direct methods, such as the transpapillary approach alone or EUS-guided TM approach alone and combined methods with transpapillary and TM approaches.
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